Trials (Turku University Hospital Cancer Centre): Revision history

14 December 2025

• curprev 14:2214:22, 14 December 2025‎ Francine talk contribs‎ 52,241 bytes +281‎ No edit summary undo

6 December 2025

• curprev 12:4212:42, 6 December 2025‎ Lucas talk contribs‎ m 51,960 bytes +1,701‎ Update categories. undo

2 December 2025

• curprev 20:2720:27, 2 December 2025‎ Francine talk contribs‎ 50,259 bytes +7‎ No edit summary undo
• curprev 14:0114:01, 2 December 2025‎ Lucas talk contribs‎ m 50,252 bytes +8,135‎ Update categories. undo

5 November 2024

• curprev 23:5423:54, 5 November 2024‎ Victor talk contribs‎ 42,117 bytes +12‎ No edit summary undo

4 January 2024

• curprev 15:2115:21, 4 January 2024‎ Francine talk contribs‎ 42,105 bytes +836‎ No edit summary undo

1 December 2023

• curprev 21:1121:11, 1 December 2023‎ Francine talk contribs‎ 41,269 bytes +41,269‎ Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to Turku University Hospital Cancer Centre page '''NCTID''': NCT03486873 '''Title''': Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) '''Study Summary''': The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in part..."